Clinical Implication of PD-L1 Expression in Patients with Endometrial Cancer

Yeorae Kim, Ala Aiob, Hyojin Kim, Dong Hoon Suh, Kidong Kim, Yong Beom Kim, Jae Hong No

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


This study investigated PD-L1 expression in endometrial cancer, its links with prognostic factors, and survival outcomes in 232 patients. Of these, 73 (31.5%) had PD-L1-positive tumors and 159 (68.5%) had PD-L1-negative tumors. PD-L1 expression significantly correlated with adverse prognostic factors. The PD-L1-positive group had higher rates of high-grade tumors (37.0% vs. 19.1%, p = 0.004), deep myometrial invasion (35.6% vs. 24.4%, p = 0.004), lymphovascular space invasion (LVSI) (39.7% vs. 25.6%, p = 0.023), and lymph node metastasis (7.2% vs. 17.1%, p = 0.024) than the PD-L1-negative group. While 5-year progression-free survival (PFS) favored the PD-L1-negative group (94.1% vs. 86.3%), this difference lacked statistical significance (p = 0.139). No significant variations emerged in overall survival (OS) (p = 0.596) or recurrence rates between the groups. Although outcomes lack statistical significance, they suggest a plausible link between PD-L1 and established adverse prognostic factors, such as histological grade, myometrial invasion depth, LVSI, and lymph node metastasis in endometrial cancer. These insights hint at PD-L1’s potential as an informal prognostic indicator, potentially aiding in endometrial cancer patient management.

Original languageEnglish
Article number2691
Issue number10
StatePublished - 1 Oct 2023

Bibliographical note

Publisher Copyright:
© 2023 by the authors.


  • PD-L1
  • clinicopathological
  • endometrial cancer
  • prognosis


Dive into the research topics of 'Clinical Implication of PD-L1 Expression in Patients with Endometrial Cancer'. Together they form a unique fingerprint.

Cite this